Genetics and immunodysfunction underlying Behçet's disease and immunomodulant treatment approaches

Area of Science:

• Immunology
• Genetics
• Autoimmune Diseases

Background:

• Behçet's disease (BD) is a chronic autoimmune disorder with unknown etiology, linked to HLA-B51.
• BD is characterized by immune dysfunctions, including altered neutrophil activity and cytokine profiles (e.g., TNF-α, IL-10, IL-1, IL-17).

Purpose of the Study:

• To comprehensively review the immunodysfunction, genetics, clinical specifications, and novel treatment strategies for Behçet's disease.
• To consolidate current understanding of BD pathogenesis and therapeutic approaches.

Main Methods:

• Literature review of studies on Behçet's disease.
• Analysis of genetic factors, including HLA-B51, gene polymorphisms (SNPs), and epigenetic modifications (DNA methylation).
• Examination of immunologic aspects such as neutrophil function, cytokine production, and microRNA expression.

Main Results:

• BD pathogenesis involves genetic predispositions (HLA-B51, SNPs in chemokine/adhesion molecules) and epigenetic changes (DNA methylation).
• Immune system abnormalities include increased neutrophil activity, elevated pro-inflammatory cytokines (TNF-α, IL-1, IL-17), and altered microRNA and IL-10 levels.
• Vascular inflammation and damage are associated with genetic polymorphisms in chemokines and adhesion molecules.

Conclusions:

• Behçet's disease pathogenesis is multifactorial, involving genetic susceptibility and immune dysregulation.
• Understanding these mechanisms informs the development of novel immunomodulant therapies for BD.
• Further research into genetic and epigenetic factors is crucial for advancing BD treatment.